Schedule 13G ownership disclosure

Zentalis Pharmaceuticals, Inc.

Common Stock · CUSIP: 98943L107

Event date: 2024-12-31

Filing-level shares
3,271,240
Percent of class
4.59%
  • The Vanguard Group

    Shares: 3,271,240 · Class: 4.59%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000275
Form type
SCHEDULE 13G/A
Filer
VANGUARD GROUP INC
CIK
CIK 102909
Filed
Jan 31, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub